Peptide-Polymer Conjugate Targeting Malaria-Infected Red Blood Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimalarial drugs, such as chloroquine and artemisinins, face increasing global resistance, and cyclic decapeptides like tyrocidines and gramicidin S, despite their potent antiplasmodial activity, are toxic due to their haemolytic effects on both infected and healthy red blood cells, making them unsuitable for systemic treatment.
Innovation Solution
A peptide-polymer conjugate is developed, where a cyclic decapeptide with specific amino acid sequences is covalently attached to a water-soluble and biocompatible polymer, forming a conjugate with a targeting ligand that selectively binds to malaria-infected red blood cells, allowing for targeted delivery and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclic decapeptides (tyrocidines, gramicidin S) are used for antimalarial treatment, then antiplasmodial activity is improved, but haemolytic toxicity increases
Solution Approach 1:
The patent uses a polymer intermediary to carry the cyclic decapeptide to the target. The polymer-conjugated peptide acts as a mediator that delivers the antiplasmodial agent specifically to infected red blood cells while the polymer carrier reduces direct contact with healthy cells, thereby maintaining therapeutic efficacy while minimizing haemolytic toxicity
Solution Approach 2:
The invention applies local quality by concentrating the peptide's antiplasmodial effect specifically at the site of infection (infected red blood cells) through targeted delivery. The peptide is delivered locally to where it is needed while avoiding widespread exposure to healthy tissues, achieving high local efficacy with reduced systemic toxicity
2Reliability
If unconjugated cyclic decapeptides are administered systemically, then antiplasmodial effect is achieved, but selectivity between infected and healthy cells decreases
Solution Approach 1:
The polymer conjugate serves as an intermediary delivery vehicle that enables selective targeting. The conjugate system mediates between the peptide drug and the target cells, using the polymer's properties to achieve preferential accumulation in infected cells while sparing healthy cells, thus improving selectivity without compromising the antiplasmodial effect
Solution Approach 2:
The invention achieves local quality by directing the therapeutic effect specifically to infected red blood cells. The conjugated peptide delivers its antiplasmodial action locally at the infection site while the polymer carrier ensures selective distribution, creating a difference in drug concentration and effect between infected and healthy cells
Data Source
AI summary
A peptide-polymer conjugate is provided for use in treating malaria infections, and in particular terminal or drug resistant malaria infections. The conjugate is formed from a polymer to which a peptide having activity against a malaria parasite is co-valently attached. The peptide is a cyclic decapeptide from the closely-related group of tyrocidines, tryptocidines, phenycidines and gramicidin S, and the polymer is a hydrophilic and biocompatible polymer with a terminal thiol, such as poly(N-vinylpyrrolidone) (PVP). The polymer chains can be decorated with a hydrophilic targeting ligand that specifically targets an epitope on red blood cells, and in particular red blood cells infected with a plasmodial parasite. A method for synthesising the peptide-polymer conjugate is also provided.